Patents Examined by F. Pierre Vandervegt
  • Patent number: 7786257
    Abstract: A novel peptide sequence having the general formula AB wherein each of A and B represent a chain of amino acid residues and wherein said A chain is capable of binding with a major histocompatibility complex on an antigen presenting cell, and wherein said B chain is capable of binding with a Signal-2 receptor on an antigen presenting cell. Preferred forms of the peptide sequence further include an X chain positioned intermediate the A chain and the B chain. Moreover, preferred forms include an A chain which has at least about 10% sequence homology with a Signal-1 moiety, or is a peptidomimetic of a Signal-1 moiety, said B chain has at least 10% sequence homology with a Signal-2 receptor moiety, or is a peptidomimetic of a Signal-2 receptor moiety, and wherein the X chain has at least one amino acid residue, or is a peptidomimetic of that amino acid residue.
    Type: Grant
    Filed: December 18, 2000
    Date of Patent: August 31, 2010
    Assignee: University of Kansas
    Inventors: Joseph S. Murray, Teruna J. Siahaan, Yongbo Hu
  • Patent number: 7767791
    Abstract: The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: August 3, 2010
    Assignee: President and Fellows of Harvard College
    Inventor: Jose Halperin
  • Patent number: 7638323
    Abstract: The present invention provides compositions and methods for treating or preventing hyperacute rejection.
    Type: Grant
    Filed: August 11, 2003
    Date of Patent: December 29, 2009
    Assignee: Recopharma AB
    Inventors: Jan Holgersson, Jining Liu, Anki Gustafsson
  • Patent number: 7638123
    Abstract: Method of treating a disease or pathological condition with activated protein C or a compound having activated protein C activity by direct regulation of the expression of specific genes associated with the disease or pathological condition.
    Type: Grant
    Filed: February 26, 2007
    Date of Patent: December 29, 2009
    Assignee: Eli Lilly and Company
    Inventors: Angelina Vucic Ciaccia, Lawrence Mark Gelbert, Brian William Grinnell, Bryan Edward Jones, David Eugene Joyce
  • Patent number: 7612180
    Abstract: Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapuetic and diagnostic, as well as research-related uses for such antibodies, are provided.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: November 3, 2009
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, Hans J. Hansen, Zhengxing Qu, Chein-Hsing Chang
  • Patent number: 7592421
    Abstract: The present invention provides peptide mimics for HLA class II antigens. The peptide mimics were identified by panning phage display peptide libraries with anti-HLA class II monoclonal antibodies. The peptide mimics inhibit the binding of an anti-HLA class II antigen antibody to HLA class II antigen positive cells and also elicit antibodies which can bind to HLA class II antigen positive cells. The identified peptide mimics can be used as immunogens for therapy of diseases related to cells expressing the HLA class II antigen, such as Non-Hodgkins Lymphoma.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: September 22, 2009
    Assignee: Health Research, Inc.
    Inventors: Soldano Ferrone, Wei Luo, Xinhui Wang
  • Patent number: 7563864
    Abstract: Celiac Sprue and/or dermatitis herpetiformis are treated by interfering with HLA binding of immunogenic gluten peptides. The antigenicity of gluten oligopeptides and the ill effects caused by an immune response thereto are decreased by administration of an HLA-binding peptide inhibitor. Such inhibitors are analogs of immunogenic gluten peptides and (i) retain the ability to bind tightly to HLA molecules; (ii) retain the proteolytic stability of these peptides; but (iii) are unable to activate disease-specific T cells.
    Type: Grant
    Filed: April 26, 2005
    Date of Patent: July 21, 2009
    Assignees: Celiac Sprue Research Foundation, Universitetet I Oslo
    Inventors: Thomas Marti, √ėyvind Molberg, Ludvig M. Sollid
  • Patent number: 7560105
    Abstract: The present invention provides novel methods for immunotherapy. The invention provides immune cells and methods to generate them, with the capacity to at least in part reduce an immune response in a host. In one aspect, the invention provides a method for generating a dendritic cell with the capacity to tolerize a T-cell for antigen the T-cell was specific for including culturing peripheral blood monocytes from an individual to differentiate into dendritic cells, activating the dendritic cells in the presence of a glucocorticoid hormone and loading the activated dendritic cell with the antigen the T-cell was specific for.
    Type: Grant
    Filed: September 21, 2000
    Date of Patent: July 14, 2009
    Assignee: Leids Universitair Medisch Centrum
    Inventors: Delphine Gabrielle Josette Rea, Cornelis Johannes Maria Melief, Rienk Offringa
  • Patent number: 7541334
    Abstract: The present invention provides an MHC class II antigen presentation enhancing hybrid polypeptide. The hybrid has an N-terminus comprising the mammalian Ii key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and modifications thereof which retain antigen presentation enhancing activity, a C-terminus comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, and an intervening chemical structure covalently linking the N-terminal and C-terminal components.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: June 2, 2009
    Assignee: Antigen Express, Inc.
    Inventors: Robert E. Humphreys, Sharlene Adams, Minzhen Xu
  • Patent number: 7541429
    Abstract: The present invention relates generally to a methodology for the isolation, purification and identification of peptide ligands presented by MHC positive cells. In particular, the methodology of the present invention relates to the isolation, purification and identification of these peptide ligands from soluble class I and class II MHC molecules which may be uninfected, infected, or tumorgenic. The methodology of the present invention broadly allows for these peptide ligands and their comcomittant source proteins thereof to be identified and used as markers for infected versus uninfected cells and/or tumorgenic versus nontumorgenic cells with said identification being useful for marking or targeting a cell for therapeutic treatment or priming the immune response against infected cells.
    Type: Grant
    Filed: October 10, 2001
    Date of Patent: June 2, 2009
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: William H. Hildebrand, Heather D. Hickman
  • Patent number: 7524936
    Abstract: The present invention relates to new genes encoding for the production of novel nox enzyme proteins involved in generation of reactive oxygen intermediates that affect cell division. The present invention also provides vectors containing these genes, cells transfected with these vectors, antibodies raised against these novel proteins, kits for detection, localization and measurement of these genes and proteins, and methods to determine the activity of drugs to affect the activity of the proteins of the present invention.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: April 28, 2009
    Assignee: Emory University
    Inventors: J. David Lambeth, Guangjie Chang
  • Patent number: 7521202
    Abstract: The field of the invention relates in general to at least one method and apparatus for the production of soluble MHC antigens and more particularly, but not by way of limitation, to at least one method and apparatus for the production of soluble Class I and II HLA molecules. The field of the invention also includes such produced soluble Class I and II HLA molecules and their use. According to the methodology of the present invention, the soluble Class I and II HLA molecules can be produced from either gDNA or cDNA starting material.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: April 21, 2009
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: William H. Hildebrand, Kiley R. Prilliman
  • Patent number: 7498147
    Abstract: Complement is recognized as an important, humoral defense system involved in the innate (nonspecific) recognition and elimination of microbial invaders, other foreign particles or molecules, and antigen-antibody complexes from the body. The present invention makes use of the surprising notion that the handling of lipids by the body, rather than its antimicrobial activity, is the primary and most ancient function of the complement system. Consequently, atherosclerosis as observed in disorders associated with disturbed lipid metabolism (familial combined hyperlipemia (FCHL), postprandial hyperlipidemia, hypertriglyceridemia with low levels of HDL cholesterol, and insulin resistance associated with type-II diabetes and obesity), is ascribed to either genetic or acquired defects in ancient (activatory and/or regulatory) complement components. Based on this new insight, novel preventive measures and treatment modalities of disturbed lipid metabolism are introduced.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: March 3, 2009
    Assignee: Crossbeta Biosciences B.V.
    Inventors: Manuel Castro Cabezas, Hans van Dijk
  • Patent number: 7439335
    Abstract: The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules with one or more accessory molecules. The matrices are used to activate naive CD4+ T cells as well as shift the ongoing activation state into a preferred differentiated population of either Th1 or Th2 cells.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: October 21, 2008
    Assignee: The Scripps Research Institute
    Inventors: Susan R. Webb, Ola Winqvist, Lars Karlsson, Michael R. Jackson, Per A. Peterson
  • Patent number: 7439330
    Abstract: The invention includes antibodies or antigen-binding fragments thereof which bind specifically to glycated CD59, compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of producing and using the antibodies or antigen-binding fragments thereof for diagnosis and treatment of diabetic conditions and diabetic-associated conditions.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: October 21, 2008
    Assignee: President and Fellows of Harvard College
    Inventor: Jose Halperin
  • Patent number: 7439331
    Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: October 21, 2008
    Assignee: Genentech, Inc.
    Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
  • Patent number: 7432364
    Abstract: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: October 7, 2008
    Assignee: Bayer HealthCare LLC
    Inventors: Clark Pan, Andreas M. Knorr, Michael Schauer, Claudia Hirth-Dietrich, Sabine Kraft, Barbara Krebs
  • Patent number: 7432356
    Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.
    Type: Grant
    Filed: August 17, 2002
    Date of Patent: October 7, 2008
    Assignee: Genentech, Inc.
    Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
  • Patent number: 7429647
    Abstract: Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient in pharmaceutical and diagnostic compositions. The Fab and their DNA sequences can also be used for the preparation of complete recombinant Anti-Rhesus D antibodies. Useful in pharmaceutical and diagnostic compositions.
    Type: Grant
    Filed: January 18, 2006
    Date of Patent: September 30, 2008
    Inventors: Andreas Morell, Martin Imboden, Beda Statler, Sylvia Miescher, Monique Vogel, Hanspeter Amstutz
  • Patent number: RE40948
    Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.
    Type: Grant
    Filed: October 24, 2001
    Date of Patent: October 27, 2009
    Assignees: The Johns Hopkins University, Astrazeneca United Kingdom, Ltd., Cancer Institute, Japanese, Foundation for Cancer Research, The University of Utah
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip Hedge, Geoff Joslyn, Alexander Fred Markham, Yusuke Nakumura, Andrew Thliveris, Raymond White